RT @ErinMichos: "The addition of evolocumab to maximally tolerated statin therapy had no impact on patient-reported cognition after an aver…
"The addition of evolocumab to maximally tolerated statin therapy had no impact on patient-reported cognition after an average of 2.2 years of treatment, even among patients who achieved LDL-C <20 mg/dl."
RT @JACCJournals: Does super-low LDL-C affect cognition? Dr. @rgiugliano et al. provide an analysis of the FOURIER trial in this week's #JA…
RT @ValleAlfonso: 👥22,655 ⏱2.2years #FOURIER ⚠️evolocumab to maximally tolerated statin therapy had no impact on patient-reported cognition…
Do “physiological levels” of LDL-C affect cognition? 😉 @ProfKausikRay @pabeda1 @SABOURETCardio @Drlipid @LipidLover1030 @lipiddoc @lansberg @skathire @ethanjweiss @DLBHATTMD @cpcannon @ErinMichos @DrMarthaGulati
RT @ValleAlfonso: 👥22,655 ⏱2.2years #FOURIER ⚠️evolocumab to maximally tolerated statin therapy had no impact on patient-reported cognition…
RT @ValleAlfonso: 👥22,655 ⏱2.2years #FOURIER ⚠️evolocumab to maximally tolerated statin therapy had no impact on patient-reported cognition…
👥22,655 ⏱2.2years #FOURIER ⚠️evolocumab to maximally tolerated statin therapy had no impact on patient-reported cognition, even among patients who achieved LDL-C <20 mg/dl 📂@jacc https://t.co/1LNyQ231nX @secardiologia https://t.co/CzmhJmJIiP
RT @JACCJournals: Does super-low LDL-C affect cognition? Dr. @rgiugliano et al. provide an analysis of the FOURIER trial in this week's #JA…
RT @JACCJournals: Does super-low LDL-C affect cognition? Dr. @rgiugliano et al. provide an analysis of the FOURIER trial in this week's #JA…
RT @Drlipid: Reassuring - The addition of PCSK9i evolocumab to maximally tolerated statin Rx had no impact on patient-reported cognition af…
RT @NutritionMadeS3: no effect on cognition of LDL-C reduction (even dramatic, <20mg/dL) expected, since lipoproteins don't cross the bloo…
.Sin datos desfavorables en seguridad, aun con LDL<20! The addition of evolocumab to maximally tolerated statin therapy had no impact on patient-reported cognition after an average of 2.2 years of treatment, even among patients with LDL-C <20 mg/dl.
Cognition After Lowering LDL-Cholesterol With Evolocumab | JACC: Journal of the American College of Cardiology https://t.co/HRTHSoYAxg
RT @JACCJournals: Does super-low LDL-C affect cognition? Dr. @rgiugliano et al. provide an analysis of the FOURIER trial in this week's #JA…
Cognition After Lowering LDL-Cholesterol With Evolocumab https://t.co/Ec6o1a9s2a @JACCJournals #SuperLowLDLC #Cognition ... no impact on patient-reported cognition after an average of 2.2 years of treatment, ☝️🙂even among patients who achieved LDL-C &
Does super-low LDL-C affect cognition? Dr. @rgiugliano et al. provide an analysis of the FOURIER trial in this week's #JACC. https://t.co/94E9dperDI #ASCVD @BrighamWomens @TIMIStudyGroup https://t.co/Rv5FLc47Qm
no effect on cognition of LDL-C reduction (even dramatic, <20mg/dL) expected, since lipoproteins don't cross the blood brain barrier and the brain produces its own cholesterol https://t.co/VnKoSPTLwt
RT @Drlipid: Reassuring - The addition of PCSK9i evolocumab to maximally tolerated statin Rx had no impact on patient-reported cognition af…
RT @Drlipid: Reassuring - The addition of PCSK9i evolocumab to maximally tolerated statin Rx had no impact on patient-reported cognition af…
RT @Drlipid: Reassuring - The addition of PCSK9i evolocumab to maximally tolerated statin Rx had no impact on patient-reported cognition af…
RT @Drlipid: Reassuring - The addition of PCSK9i evolocumab to maximally tolerated statin Rx had no impact on patient-reported cognition af…
Reassuring - The addition of PCSK9i evolocumab to maximally tolerated statin Rx had no impact on patient-reported cognition after an average of 2.2 years of treatment, even among patients who achieved LDL-C <20 mg/dL. Also see editorial in same issue ht
LDL<20 does not significantly impair cognition https://t.co/ciWvXTbd7h
Cognition After Lowering LDL-Cholesterol With Evolocumab | JACC: Journal of the American College of Cardiology https://t.co/YjYklMSMy7
RT @gpokmd: Cognition After Lowering LDL-Cholesterol With Evolocumab -(NO EFFECT) ScienceDirect https://t.co/trFIANqtTw
RT @gpokmd: Cognition After Lowering LDL-Cholesterol With Evolocumab -(NO EFFECT) ScienceDirect https://t.co/trFIANqtTw
RT @gpokmd: Cognition After Lowering LDL-Cholesterol With Evolocumab -(NO EFFECT) ScienceDirect https://t.co/trFIANqtTw
Cognition After Lowering LDL-Cholesterol With Evolocumab -(NO EFFECT) ScienceDirect https://t.co/trFIANqtTw
RT @FormigaFrancesc: Cognition After Lowering LDL-Cholesterol With Evolocumab https://t.co/i9obKuZbIn
RT @TIMIStudyGroup: Adding #evolocumab to max tolerated #statin did not affect patient-reported #cognition among 22,655 participants in #FO…
Cognition After Lowering LDL-Cholesterol With Evolocumab https://t.co/i9obKuZbIn
RT @TIMIStudyGroup: Adding #evolocumab to max tolerated #statin did not affect patient-reported #cognition among 22,655 participants in #FO…
Adding #evolocumab to max tolerated #statin did not affect patient-reported #cognition among 22,655 participants in #FOURIER-results published in @JACCJournals @rgiugliano @brighamwomens https://t.co/vQ0kOFHYFK